(Reuters) - NEW YORK, July 18 - Abbott Laboratories Inc. posted higher second-quarter earnings Wednesday on increased sales of its prescription drugs, with global revenue from arthritis treatment Humira jumping 50 percent.
The suburban Chicago company said it earned $989 million, or 63 cents per share, up from $612 million, or 40 cents per share, a year earlier, when Abbott took charges related to its acquisition of the vascular business of Guidant Corp. Excluding special items, Abbott earned 69 cents per share. On that basis, analysts on average expected 68 cents per share, according to Reuters Estimates.
Read more at Reuters.com Market News
The suburban Chicago company said it earned $989 million, or 63 cents per share, up from $612 million, or 40 cents per share, a year earlier, when Abbott took charges related to its acquisition of the vascular business of Guidant Corp. Excluding special items, Abbott earned 69 cents per share. On that basis, analysts on average expected 68 cents per share, according to Reuters Estimates.
Read more at Reuters.com Market News
No comments:
Post a Comment